Mode
Text Size
Log in / Sign up
Phase 3 Completed N=860 Randomized Triple-blind Treatment

Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception

Emergency Contraception
Source: ClinicalTrials.gov NCT03614494 ↗
Enrolled (actual)
860
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Percentage of Pregnancies Prevented — 94.7; 63.3 percentage of pregnancies prevented — p=<0.0001
◆ Published Evidence
Established
22citations · ~7 / year
Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
Lancet (London, England) · 2023 · Open access · Likely link

Summary

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.

Linked Publications

  • Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
    Lancet (London, England) · 2023 · 22 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Pregnancies Prevented
94.7; 63.3 <0.0001 sig
SECONDARY
Pregnancy Rate
1; 7 0.036 sig

Eligibility Criteria

Inclusion Criteria

  • healthy women aged 18 years or above;
  • requesting emergency contraception within 72 h of a single act of unprotected intercourse in the current menstrual cycle;
  • having menstrual cycles between 24 and 42 days
  • willing to abstain from further acts of unprotected intercourse and;
  • available for follow-up over the next 6 weeks.

Exclusion Criteria

  • post-abortion or postpartum and period have not yet returned,
  • being on prescription drugs currently
  • having unprotected intercourse in this cycle more than 72 hours or more than once before attending the clinic,
  • being found pregnant at the time of presentation,
  • breastfeeding,
  • having been sterilized (or partner having been sterilized) or having intrauterine contraceptive device in-situ,
  • uncertain about the date of the last menstrual period,
  • having used hormonal contraceptive (including EC pill) or NSAID in the current or past one cycle,
  • having history of asthma, urticarial or other allergic reactions to piroxicam, aspirin or other NSAIDs,
  • having history of ischaemic heart disease in the past one year
  • having history of pelvic ulcer disease and/or gastrointestinal bleeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03614494) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search